Le Lézard
Classified in: Health
Subjects: TDS, TRI, FVT

Bridge to Life Announces Abstract Presentations at The 2024 International Congress of the International Liver Transplantation Society (ILTS) in Houston, Texas, May 1-4, 2024


CHICAGO, April 11, 2024 /PRNewswire/ -- Bridge to Life Ltd, a renowned market leader in organ preservation solutions, today announced the presentation of five accepted abstracts, including a late-breaker, at the 2024 International Congress of the International Liver Transplantation Society (ILTS). The conference is scheduled to take place in Houston, Texas, from May 1-4, 2024.

Abstracts to highlight hypothermic oxygenated machine perfusion in liver transplants

All abstract posters will be available for viewing as ePosters at the searchable ePoster terminals in the ePoster area of the Congress Center. Poster viewing sessions will be held throughout the four days of the Congress.

Abstracts to be presented:

LATE BREAKER: Machine perfusion in liver transplantation; Cochrane review and meta-analysis, S. Tingle, MD, et al, Newcastle University, Translational and Clinical Research Institute, Newcastle, United Kingdom

Hypothermic oxygenated perfusion (HOPE): Results of our experience in the first 31 liver transplants, Dora Gomez Pasantes, MD et al, University Hospital of A Coruña, A Coruña, Spain; Abstract Number: eP-214

Impact of hypothermic organ perfusion in small grafts in living donor liver transplantation to avoid small-for-size syndrome: safety & feasibility pilot study- phase-I HOPE-L trial, M. Pardasani, MD, M. Rela, MD et al, Dr Rela Institute and Medical Centre, Bharath Institute of Higher Education and Research, Chennai, India

Single center evolution of DCD donor utilization for liver transplantation: from perceived marginality to routine and beyond, Matteo Ravaioli, MD, PhD, et al, University of Bologna, Bologna, Italy; Abstract Number: eP-194

Machine perfusion, an ace up your sleeve: unlocking liver graft potential from donation after circulatory death and previously rejected extended criteria donors, Matteo Ravaioli, MD, PhD, et al, University of Bologna, Bologna, Italy; Abstract Number: eP-191

About Bridge to Life Ltd

Bridge to Life Ltd is a market leader in organ preservation solutions, offering premier products such as Belzer UW, EasiSlush and the VitaSmart1 hypothermic oxygenated perfusion system.  With a strong focus on product quality, innovation and accessibility, the company serves and partners with leading Transplant Centers and Organ Procurement Offices (OPO) globally.

1 VitaSmart is CE Marked and available for sale in several markets outside of the United States. VitaSmart is not approved for sale in the US. The company successfully completed its pivotal, multicenter, randomized clinical study in the US in 2023 and expects to submit its Premarket Approval submission to FDA later this year.

SOURCE Bridge to Life Ltd.


These press releases may also interest you

at 21:03
EHA 2024 | Results from Five Studies of Ascentage Pharma's Key Drug Candidates Selected for Presentations at 2024 European Hematology Association Hybrid Congress
Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that the latest results from five studies have been selected for...

at 21:00
Bristol Myers Squibb's CAR T Cell Therapy Breyanzi Approved by the U.S. Food and Drug Administration for Relapsed or Refractory Follicular Lymphoma
Bristol Myers Squibb today announced the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Breyanzi® (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, for the treatment...

at 20:54
Starlight Children's Foundation CEO, Adam Garone, Named Nonprofit Executive of the Year by Los Angeles Business Journal
Starlight Children's Foundation CEO, Adam Garone, has been named Nonprofit Executive of the Year (Large), by the Los Angeles Business Journal. The prestigious award was presented at the annual Nonprofit and Corporate Citizenship Award luncheon held...

at 20:35
InnoCare Announces the Completion of Patient Enrollment in the Phase II Clinical Trial of ICP-488 for the Treatment of Psoriasis
InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, today announced the completion of patient enrollment for the phase II clinical trial of ICP-488, a TYK2...

at 19:56
Rare Cannabinoid Company Launches Dispensary-Strength CBG + CBD + THC Rapid Relief Gel With Free Sample Offer
Rare Cannabinoid Company is proud to announce the launch of its new,...

at 18:58
Children's Health and UT Southwestern Receive $100 Million Donation from the Pogue Family for New $5 Billion Dallas Pediatric Campus
Children's HealthSM and UT Southwestern Medical Center announced a historic gift of $100 million from the Jean and Mack Pogue family in support of the $5 billion new Dallas pediatric campus, unveiled earlier this year. The gift from the Pogue...

More news about Health...


News published on and distributed by: